Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Cytarabine and Mitoxantrone for Refractory/Relapsed AML
NCT00015951Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Apr 2001
- Primary completion
- Apr 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Maryland, Baltimore. Primary endpoint: Clinical Effectiveness. Started Apr 2001; status: completed.
02
Drugs
bevacizumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00015951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00015951.